ABSI
Price
$2.62
Change
-$0.09 (-3.32%)
Updated
Jun 27 closing price
Capitalization
333.57M
52 days until earnings call
BEAM
Price
$16.80
Change
-$0.34 (-1.98%)
Updated
Jun 27 closing price
Capitalization
1.69B
45 days until earnings call
Interact to see
Advertisement

ABSI vs BEAM

Header iconABSI vs BEAM Comparison
Open Charts ABSI vs BEAMBanner chart's image
Absci
Price$2.62
Change-$0.09 (-3.32%)
Volume$7.4M
Capitalization333.57M
Beam Therapeutics
Price$16.80
Change-$0.34 (-1.98%)
Volume$4.49M
Capitalization1.69B
ABSI vs BEAM Comparison Chart in %
Loading...
ABSI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABSI vs. BEAM commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Hold and BEAM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ABSI: $2.62 vs. BEAM: $16.80)
Brand notoriety: ABSI and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABSI: 244% vs. BEAM: 238%
Market capitalization -- ABSI: $333.57M vs. BEAM: $1.69B
ABSI [@Biotechnology] is valued at $333.57M. BEAM’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABSI’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • ABSI’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABSI and BEAM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABSI’s TA Score shows that 2 TA indicator(s) are bullish while BEAM’s TA Score has 3 bullish TA indicator(s).

  • ABSI’s TA Score: 2 bullish, 6 bearish.
  • BEAM’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ABSI.

Price Growth

ABSI (@Biotechnology) experienced а -6.09% price change this week, while BEAM (@Biotechnology) price change was +0.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ABSI is expected to report earnings on Aug 19, 2025.

BEAM is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.69B) has a higher market cap than ABSI($334M). ABSI YTD gains are higher at: 0.000 vs. BEAM (-32.258). ABSI has higher annual earnings (EBITDA): -93.91M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. ABSI (134M). ABSI has less debt than BEAM: ABSI (8.92M) vs BEAM (158M). BEAM has higher revenues than ABSI: BEAM (63.6M) vs ABSI (4.82M).
ABSIBEAMABSI / BEAM
Capitalization334M1.69B20%
EBITDA-93.91M-399.03M24%
Gain YTD0.000-32.258-
P/E RatioN/AN/A-
Revenue4.82M63.6M8%
Total Cash134M1.22B11%
Total Debt8.92M158M6%
TECHNICAL ANALYSIS
Technical Analysis
ABSIBEAM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
89%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 13 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ABSI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCGYX19.810.24
+1.23%
NYLI PineStone Global Equity Class C
NBFCX34.140.27
+0.80%
Neuberger Berman Focus Trust
RYANX137.441.03
+0.76%
Rydex Nova A
PGELX27.110.06
+0.22%
George Putnam Balanced R5
HBLYX14.85N/A
N/A
Hartford Balanced Income Y

ABSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABSI has been loosely correlated with RXRX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ABSI jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABSI
1D Price
Change %
ABSI100%
-3.32%
RXRX - ABSI
61%
Loosely correlated
-6.85%
CRSP - ABSI
60%
Loosely correlated
+1.69%
BEAM - ABSI
58%
Loosely correlated
-1.98%
ABCL - ABSI
58%
Loosely correlated
-3.48%
IMNM - ABSI
50%
Loosely correlated
-0.23%
More

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.98%
CRSP - BEAM
71%
Closely correlated
+1.69%
RXRX - BEAM
64%
Loosely correlated
-6.85%
NTLA - BEAM
63%
Loosely correlated
-0.52%
DNLI - BEAM
61%
Loosely correlated
-2.69%
SYRE - BEAM
59%
Loosely correlated
-4.99%
More